Press Release: Euclises : Euclises Pharmaceuticals, Inc. to Present Preclinical Efficacy Results at American Association for Cancer Research

ST. LOUIS--(BUSINESS WIRE)--Euclises Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel COX-2 inhibitors for the treatment of cancer, is pleased to announce that its Late-Breaking Abstract has been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans on April 19, 2016. Entitled, "Anti-tumor effects of ECP-1014 in combination with erlotinib in HT-29 xenograft murine colon carcinoma model,"